Symptom-based stratification of autoimmune diseases

For many autoimmune diseases, definitions of disease and patient heterogeneity are major concerns. Response to treatment varies greatly between patients, and this variability might obstruct clinical trials. Many drug candidates have not shown efficacy in patients with systemic autoimmune diseases and thus will not reach the market, despite excellent responses in individual patients or subgroups of patients. Stratification of patients is therefore of high priority, but no validated biomarkers to define relevant subgroups of patients with primary Sjögren's syndrome exist. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trialsStratification on the basis of patient-reported symptoms of patients with primary Sjögren's syndrome revealed distinct pathobiological endotypes with distinct responses to immunomodulatory treatments. Our data have important implications for clinical management, trial design, and therapeutic development. Similar stratification approaches might be useful for patients with other chronic immune-mediated diseases. Full-Text PDF Open AccessCorrection to Lancet Rheumatol 2019; 1: e76–77Idborg H. Symptom-based stratification of autoimmune diseases. Lancet Rheumatol 2019; 1: e76–77—In this Comment, the figure legend has been corrected. This correction has been made as of Nov 26, 2019. Full-Text PDF